Pharmasyntez-Nord and Gan & Lee Pharmaceuticals signed Memorandum of Understanding

On October 18, Pharmasyntez-Nord JSC and Gan & Lee Pharmaceuticals, the largest producer of insulin in China, signed a Memorandum of Understanding at the thematic forum on local cooperation within the Third International Forum of the Belt and Road Initiative.

It’s worth reminding that the Belt and Road Initiative forum was proposed by Chinese leader Xi Jinping 10 years ago. The project involves more than 150 countries and more than 30 international organizations. The initiative has raised significant investments, created new jobs and promoted cooperation in various areas.

Within the framework of the Memorandum signed during the international forum, it is planned to produce medicinal products, including various types of insulins, at Pharmasyntez-Nord's facilities using Gan & Lee Pharmaceuticals technologies. 

As noted by M.Yu. Kvasnikov, CEO of Pharmasyntez-Nord JSC, today the problem of ensuring drug supply safety is given special attention both in Russia and in other countries. The strategic partnership between Pharmasyntez-Nord and Gan & Lee Pharmaceuticals will contribute to bringing to the EAEU market both well-known and innovative drugs that are vital for millions of people, as well as increasing the availability of medicinal products. Furthermore, the cooperation will become another step in strengthening the trade and scientific potential of both Russia and China and in developing an active bilateral dialog at all levels.

Pharmasyntez-Nord JSC is a unique research and production complex specializing in the development and production of modern and effective drugs, including various types of insulins. It already produces three types of recombinant human insulin (gensulins): Gensulin M30, Gensulin N, Gensulin R. In August 2023, production of insulin glargine, the first long-acting recombinant analog insulin, was launched.  

Today, the plant's insulin production capacity is more than 5 million units per year. Available presentations include vials, disposable pre-filled syringes, and cartridges for reusable pre-filled syringes. 

"Cooperation under the signed Memorandum will allow Pharmasyntez-Nord JSC to expand the list of insulin active pharmaceutical substances produced, as well as to increase their production volume. This will contribute to a comprehensive solution to the important task of providing patients with high-quality Russian analogs of vital and essential drugs," M.Yu. Kvasnikov emphasized.